Background and aims: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 /
Introduction
In December 2019, an outbreak of pneumonia of unknown etiology in Wuhan, Hubei province, China led to the identification of a new betacoronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 . SARS-CoV-2 is the seventh identified coronavirus that is able to infect humans 2 . In addition to animal origin it shares up to 80% of the gene sequence with other members of coronavirus family, such as severe acute respiratory syndrome coronavirus (SARSCoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) 2, 3 . Our understanding of SARS human-to-human transmission is still evolving, but is currently believed to occur through air droplets, although fecal oral spread and airborne transmission may be other sources of transmission 4, 5 . In a short time, the highly contagious virus has caused a pandemic, destabilizing health systems, economies, and governments around the world 6 .
SARS-CoV-2 infection can be asymptomatic or be associated with the coronavirus disease 2019
(COVID-19), which has a spectrum of respiratory clinical manifestations ranging from fever, dry cough, and dyspnea to pneumonia, pulmonary oedema, acute respiratory distress syndrome (ARDS), and multiple organ failures, requiring hospitalization in intensive care unit (ICU) and leading to death in severe cases 7 . Less common symptoms include headache, haemoptysis, nausea, vomiting, and diarrhea 8 . Although initially found in a small percentage of cases, an increasing number of patients present with diarrhea 9 . Diarrhea is a frequent symptom in coronavirus infections;
it was detected in up to 30% of patients with MERS-CoV and 10.6% of patients with SARSCoV 10, 11 . The purpose of this review is to examine the literature on the epidemiology, clinical symptoms, mechanism of action, management, and prevention of COVID 2019 associated diarrhea in order to better characterize this symptom and to identify any preventive measures for patients exposed to virus.
Methods
We searched PubMed, EMBASE, and Web of Science up to March 2020 in order to identify all studies documenting the presence of diarrhea in patients with confirmed diagnosis of COVID-19.
The following search terms alone or matched with the Boolean operators "AND" or "OR" were used: "COVID-19", "SARS-CoV-2", "coronavirus", "pandemic", "epidemic", "outbreak", "diarrhea", "gastrointestinal symptom", "stool", "feces". No temporal, study design, or language restrictions were applied. We focused on full-text articles, but abstracts were considered if relevant.
Additional studies were identified through the accurate evaluation of the reference list of the included works.
Etiopathogenesis of SARS-CoV associated diarrhea
Coronaviruses are a family of single-stranded enveloped RNA viruses and their genome have a number of open reading frames (ORFs) ranging from six to eleven 12 . The first ORF contains most of the viral genome and encodes 16 non-structural proteins, while the other ORFs encode structural and accessory proteins 13, 14 . The remaining viral genome is responsible for the expression of 4 essential structural proteins, including spike glycoprotein, small envelope protein, matrix protein, and nucleocapsid protein 13, 14 . The SARS-CoV entry into a host cell is mediated by the interaction between the envelope-anchored viral spike protein and the host receptor, consisting of angiotensinconverting enzyme 2 (ACE2) 13 . Genomic characterization of SARS-CoV-2 showed a high homology degree between SARS-CoV-2 and SARS-CoV as regards the receptor-binding domain structure, indicating that the new virus could bind ACE2 and infect humans (Figure 1 ) 3 . The spike protein is functionally made up of two subunits, S1 and S2 13 . SARS-2-S uses ACE2 for entry 15 . The former mediates virus attachment to the host cell membrane, while the latter favors the fusion of the two cell membranes 16 . This process requires priming by cellular serine proteases (TMPRSS2), which allow spike protein cleavage, regulating the entire mechanism 16 . The virus infectivity mainly depends on binding affinity with ACE2 receptor 17 . Structural studies 17 showed that the new SARS- Although the specific mechanisms involved in diarrhea pathogenesis are not entirely known, viral infection is likely to cause an alteration of intestinal permeability, resulting in enterocyte malabsorption 4 . In addition, it has been proposed that intestinal ACE2 is involved in the uptake of dietary amino acids, regulating the expression of antimicrobial peptides and promoting the homeostasis of the gut microbiome 21 . Mouse models showed that the presence of ACE2 alterations was associated with colitis, suggesting that virus activity may cause enzyme modifications, increasing the susceptibility to intestinal inflammation and diarrhea 21 . Further studies are needed to clarify the mechanisms underlying diarrhea in these viral infections and to define the correlation between respiratory and gastrointestinal symptoms 22 .
Epidemiology of COVID -19 associated diarrhea
Epidemiological data of COVID-19 patients with diarrhea are summarized in 27 . In addition, in a 78-year-old patient with severe respiratory distress treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO), endoscopic procedures were performed following signs of bleeding (coffee ground material from the nasogastric tube and positive fecal occult blood test) 27 . No mucosal damage was identified, but multiple esophageal, gastric, duodenal, and rectal biopsies were performed 27 . Histological analysis revealed a high percentage of ACE2 protein in the glandular cells of all examined segments, with the exception of the esophagus (mainly characterized by squamous cells), supporting the theory of a possible effect of the virus on these organs 27 . An 81-year-old Japanese woman with COVID-19 had watery diarrhea and the virus was detected in the stool for up to 15 days after disease onset 28 . In a descriptive case series 29 of the first 18 COVID-19 cases in Singapore, 3 patients had diarrhea (16.6%). None of these 3 patients had complications and none required supplemental oxygen 29 .
Stool samples were tested by real-time reverse transcriptase -polymerase chain reaction (RT-PCR) and SARS-CoV-2 was found in 4/8 patients (50%) from day 1 to day 7 29 . In a small case series 30 , data from 5 patients tested positive for both SARS-CoV-2 and influenza virus were analyzed, reporting diarrhea in 2 cases (40%). An analysis on the clinical characteristics of 30 medical members (22 doctors and 8 nurses) with COVID-19 showed the presence of diarrhea in 9/30 subjects (30%) 31 . Recently, the first study specifically designed to evaluate patients with gastrointestinal symptoms at disease onset was published 32 . One hundred eighty-three patients were included, and diarrhea was detected in 68 cases (37.1%). COVID-19 epidemiological data in children are lacking, however in a recent analysis 33 of 171 children with a median age of 6.7 years, diarrhea was reported in 8.8% (15) 
Characteristics of COVID-19 associated diarrhea
Jin et al. 35 defined diarrhea as the passing of loose stools >3 times per day. In their retrospective study, 53/651 patients (81.4%) had diarrhea at onset and the median symptom duration was 4 days 35 . The evidence presented by Chan et al. 10 provided data from a family cluster with COVID-19. Two out of 7 patients experienced 3 to 4 days of diarrhea with a number of evacuations ranging from 5 to 8 per day 10 . On the other hand, in a 22-year-old young man 36 , diarrhea resulted in a lower number of evacuations (3 to 4 per day) and was associated with a low-grade fever. Interestingly, these symptoms disappeared after antiviral therapy (oral lopinavir and ritonavir), supporting the link between symptom and COVID-19 disease 36 . The first known case of COVID-19 in the United
States also showed diarrheal symptoms for two consecutive days 37 . A stool sample was collected following loose bowel movements to verify the presence of the virus 37 . Importantly, the test was positive 7 days after the presumed onset of the disease, showing a high viral load 37 . Unfortunately, in the remaining studies diarrhea was not well characterized and no data were available regarding the total number of evacuations, consistency of the stools (Bristol scale), and duration of symptoms.
Prognostic implications of diarrhea
A symptom analysis based on COVID-19 severity (according to the American Thoracic Society guidelines for community-acquired pneumonia) showed a greater diarrhea percentage in patients with severe disease compared to those with non-severe disease (5.8% vs 3.5% respectively),
suggesting an association between presence of symptom and disease severity 23 . Likewise, COVID-19 patients with diarrhea, nausea, and vomiting were more likely to require mechanical ventilation and had ARDS compared to patients without gastrointestinal symptoms (6.76% vs 2.08%, p=0.034, and 6.76% vs 2.08%, p=0.034, respectively) 35 . On the other hand, a case series of 138 patients found that diarrhea was present in 14 patients (10.1%) at disease onset and it was not associated with greater need for ICU care 7 . Another study compared the characteristics of COVID-19 patients who were underwent regular hospital management with patients who had more severe disease requiring mechanical ventilation or intensive care; the purpose of this analysi was to identify factors associated with poor prognosis in COVID-19. 38 . Among the 155 included patients, diarrhea occurred in 5 patients with severe disease and in 2 cases in the standard management group 38 .
Although this finding suggested a worse prognosis in patients with diarrhea, no correlation was found 38 . Additional studies are needed to clarify the correlation between diarrhea and the outcomes of COVID-19 patients.
Lessons from other coronavirus infections
Intestinal involvement and diarrhea in association with respiratory symptoms are common features to the other members of the coronavirus family 13 . A retrospective study evaluated the up to 10 weeks after the onset of symptoms 39 . Data from Toronto SARS patients confirmed the incidence rates of diarrhea, which was reported in 23.6% of the infected patients 40 . However, inanother study by Peiris et al. 41 diarrhea was present in 1% of patients at onset, but 73% of infected people developed watery diarrhea after about one week. In regards to MERS, a descriptive study showed the presence of diarrhea in 12 cases (26%) 42 . In a study 43 on 186 MERS patients, diarrhea occurred in 26 subjects (14%). However, analyzing the data based on survival, a greater number of subjects who survived had diarrheal symptoms compared to the deceased (76.5% vs 46.4%, p = 0.05), indicating a less severe disease and a better prognosis in patients with diarrhea 43 . Another study 44 compared the clinical characteristics of medical staff and patients with MERS, and found a higher percentage of diarrheal symptoms in the former than in the latter (11 cases, 50% vs 5 cases, 23%, p value non-significant).
Prevention
So far, no vaccines have been developed to prevent COVID-19, but several potential vaccines are being tested (NCT04299724, NCT04276896, NCT04313127, and NCT04283461). The current precautions adopted to contain the infection are standard measures for respiratory viral pathologies, including the use of masks and gloves, frequent hand hygiene (alcohol-based disinfectants or soap and water), travel restrictions, and avoiding contact with people suspected or confirmed to be infected 45 . The presence of virus in the stool and its long fecal persistence time suggest that orofecal transmission is possible, leading to several implications and requiring additional precautions.
First of all, contact with possible sources of contamination (e.g. saliva, vomiting, and feces) should be avoided with a greater attention to hygiene. 22 . Secondly, outpatient management should be modified. Deferable gastroenterologic consultations and non-urgent endoscopic procedures should be rescheduled and each patient should be stratified according to the symptoms or based on possible contact with infected people or origin from high-risk areas 46 . Personal protective equipment (PPE) including gloves, goggles, gowns, and respiratory protective devices should be adopted by healthcare professionals of the endoscopy units to avoid spreading the virus (Table 3) 46 . Thirdly, all candidates for fecal microbiota transplantation and healthy donors should be screened for the virus 47 . In addition, animal models showed that ACE and angiontensin receptor inhibition were associated with an increase in circulating ACE2 levels 48 . Based on diarrhea etiopathogenesis and on the key role of ACE2, the use of ACE or angiontensin receptor (AR) blockers should be investigated, particularly in elderly or cardiovascular patients, as it could lead to a higher risk of developing COVID-19 diarrhea 49 . Importantly, this hypothesis is not confirmed, and further
investigations are needed to demonstrate whether the use of ACE/AR inhibitors is a risk factor for COVID-19.
Treatment
Currently there is no specific treatment for COVID-19 and its management is mainly based on supportive care. No evidence on the efficacy of anti-diarrheal drugs is available, but an adequate rehydration and potassium monitoring should be performed as in all patients with diarrhea 50 . It is important to underline that antibiotics and antivirals are often used for COVID-19 treatment, involving a likely alteration of the gut microbiota and causing diarrhea 51, 52 . It is therefore plausible that the gut microbiota could be a new therapeutic target and that probiotics could have a role in the management of these patients 22, 53 . Interestingly, the China's National Health Commission recommended the use of probiotics for the treatment of patients with severe COVID-19 in order to preserve intestinal balance and to prevent secondary bacterial infections 22 . Moreover, a rapid improvement in diarrhea was also found after starting antiviral therapy 36 . Although no antiviral drug was specifically designed for the treatment of diarrhea, several molecules could have beneficial effects. Some monoclonal antibodies target the receptor-binding domain of the spike protein to inhibit the contact between the virus and ACE2 54 . Other attractive target is the TMPRSS2 protease, which plays a crucial role for viral infection 16 . Camostat mesylate a known effective inhibitor of TMPRSS2 and is already approved(in Japan for management of non-infectious conditions, such as chronic parncreatitis and reflux esophagitis; it is possible that this agent may work for COVID-19 20 .
A randomized, controlled, open-label trial evaluated the efficacy of lopinavir -ritonavir combination, two protease inhibitors, for the treatment of patients with confirmed diagnosis of COVID-19 55 . Unfortunately, no significant clinical improvement was found with this therapy 55 .
Remdesivir is a nucleotide analogue that prevents viral replication and that was effective (in combination with chloroquine) in blocking SARS-CoV-2 infection in vitro 56 . Chloroquine and hydroxychloroquine were used for the treatment of SARS and MERS and were effective in reducing coronavirus replication 57 . In in vitro studies, both drugs reduced SARS-CoV-2 replication, but hydroxychloroquine had greater inhibitory power than chloroquine 57 . A systematic review 59 . Finally, the use of baricitinib, a JAK kinase inhibitor, was proposed for the treatment of COVID-19 60 . It blocks both the AP2-associated protein kinase 1 (AAK1) and the cyclin G-associated kinase, which are two important regulators of cellular endocytosis, resulting in a theoretical reduction of the viral passage into the host cell 60 . The anti-inflammatory function and the anti-endocytic activity of baricitinib could be effective in diarrhea and deserve further studies 60 .
Discussion
In the current SARS-CoV-2 pandemic, most of the attention is still exclusively focused on the respiratory symptoms of the disease. However, it is important to emphasize that the number of COVID-19 patients experiencing diarrhea is significant and cannot be overlooked. We found high variability among published studies in the percentage of patients with diarrhea, ranging from 2% to 50% of cases. Our pooled analysis of the available data revealed an overall diarrhea rate of about It was estimated that around 86% of the infections were not documented and that patients with undocumented cases led to the contagion of most of the identified patients (79%) 65 . SARS-CoV-2 is similar to SARS-CoV and MERS-CoV, but it is transmitted faster than its predecessors and for this reason a rapid and optimal diagnostic approach is essential to contain the virus dissemination 66 . The evidence of SARS-CoV-2 in the stools and in gastrointestinal histological samples and its prolongedpersistence at the stool compared to nasopharyngeal swabs strongly suggests that orofecal transmission is possible, justifying the execution of fecal PCR in suspect patients 27 . The homology between SARS-CoV-2 and SARS-CoV and MERS-CoV and the high capacity of these viruses to resist for long periods (even two weeks) at low temperatures and for a few days at temperatures between 20°C and 30 °C is a further confirmation of possible orofecal tranmission and requires an enhancement of preventive hygiene measures 67 .
In conclusion, the presence of diarrhea should generate suspicion of a possible SARS-CoV-2 infection and should be investigated in order to reach an early diagnosis of COVID-19. The incidence of diarrhea is currently underestimated and further studies are needed to quantify the exact burden of diarrhea to compare the sensitivity of fecal and nasopharyngeal tests, to evaluate whether diarrhea is a predictive factor for prognosis, and to clarify the effects of COVID-19 in patients with underlying gastrointestinal diseases. n: number; na: not available * The systematic review and meta-analysis of Li was not included in the analysis to prevent some studies from being considered twice • Wear gloves, mask, protective gown and goggles every time you visit a patient with diarrhea.
Figure Legends
• Pay attention to hand hygiene before and after visiting a patient with diarrhea, using alcoholic disinfectants or soap and water.
• Patients with diarrhea should have a personal bathroom and bathroom sanitation should be performed several times per day
• All endoscopes and reusable accessories should be reprocessed with standard reprocessing procedures
